Holen Sie sich die Stockscreener-App
21.62
1.93%
0.43
Schlusskurs vom Vortag:
$21.19
Offen:
$20.7
24-Stunden-Volumen:
379.59K
Relative Volume:
0.37
Marktkapitalisierung:
$1.47B
Einnahmen:
$2.74B
Nettoeinkommen (Verlust:
$-441.40M
KGV:
-3.3058
EPS:
-6.54
Netto-Cashflow:
$13.00M
1W Leistung:
-4.85%
1M Leistung:
-24.71%
6M Leistung:
-24.69%
1J Leistung:
-45.55%
1-Tages-Spanne:
$20.65
$21.93
1-Wochen-Bereich:
$20.59
$22.76
52-Wochen-Spanne:
$19.50
$41.40
Quidelortho Corporation Stock (QDEL) Company Profile
Firmenname
Quidelortho Corporation
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
21.62 | 1.44B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
111.26 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
371.26 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
92.79 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.29 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.02 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corporation Aktie (QDEL) Neueste Nachrichten
American Century Companies Inc. Raises Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
QuidelOrtho at Raymond James Conference: Strategic Growth Insights - Investing.com Nigeria
QuidelOrtho at Raymond James Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
QuidelOrtho Stock Challenges: Revenue, Cash Flow, and ROIC TrendsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement - Sahm
QuidelOrtho Corporation (QDEL) Stock Analysis: Potential Upside of Over 50% Amidst Strategic Positioning in Healthcare - DirectorsTalk Interviews
Segall Bryant & Hamill LLC Sells 71,044 Shares of QuidelOrtho Corporation $QDEL - MarketBeat
Vanguard Group Inc. Has $224.89 Million Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
QuidelOrtho Corp reports results for the quarter ended March 31Earnings Summary - TradingView
QuidelOrtho (QDEL) Q4 2025 Earnings Transcript - AOL.com
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - The Motley Fool
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - The Motley Fool
QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
QuidelOrtho Q4 2025 slides: Revenue beats expectations despite 27% EPS drop - Investing.com Nigeria
Should QuidelOrtho’s (QDEL) Lifotronic Immunoassay Expansion Require Action From QDEL Investors? - simplywall.st
Why The QuidelOrtho (QDEL) Story Is Shifting As Analysts Rework Growth And Valuation Assumptions - Yahoo Finance
Is QuidelOrtho Corporation a defensive stockJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Has QuidelOrtho (QDEL) Become A Potential Opportunity After Its Sharp Share Price Slide - simplywall.st
QuidelOrtho Corp. Stock Hits Day Low of $21.14 Amid Price Pressure - Markets Mojo
QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 63.60% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Earnings Miss: Is QuidelOrtho Corporation a defensive stock2025 Volatility Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know - Finviz
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2025 earnings call transcript - MSN
Quidelortho Faces Material Risk from Weak Internal Controls and Sarbanes–Oxley Compliance Challenges - TipRanks
Decoding QuidelOrtho Corp (QDEL): A Strategic SWOT Insight - GuruFocus
Can QuidelOrtho’s (QDEL) Lifotronic Deal Reshape Its Global Immunoassay Competitiveness Story? - Yahoo Finance
Faster Cardiac Answers with High‑Sensitivity Troponin - PR Newswire
QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion - MSN
QuidelOrtho (NASDAQ:QDEL) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
QuidelOrtho Corp SEC 10-K Report - TradingView
QuidelOrtho Earnings Call: Growth, Margins And Risks - TipRanks
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference - marketscreener.com
The Top 5 Analyst Questions From QuidelOrtho's Q4 Earnings Call - Finviz
QuidelOrtho Partnership Targets Expanded Immunoassay Reach in International Markets - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Global Immunoassay Expansion - TipRanks
QuidelOrtho plans March 3 talk at Raymond James investor conference - Stock Titan
QuidelOrtho–Lifotronic Partnership Targets Immunoassay Expansion in International Markets - TipRanks
Surprises Report: Is QuidelOrtho Corporation a turnaround storyMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
The Top 5 Analyst Questions From QuidelOrtho’s Q4 Earnings Call - Yahoo Finance
QuidelOrtho Expands in Mexico With Lifotronic Deal - Mexico Business News
QuidelOrtho Expands Global Immunoassay Offering Through Lifotronic Partnership - TipRanks
QuidelOrtho Corporation (QDEL): Analyzing Its 47% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio - Finviz
QDEL stock slumps on mixed Wall Street price target revisions after Q4 report - MSN
QuidelOrtho enters strategic supply agreement to expand global immunoassay portfolio - BioSpectrum Asia
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio – Company Announcement - Financial Times
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic - Intellectia AI
QuidelOrtho Q4 results beat on both lines, but issues weak 2026 EPS guidance - MSN
Finanzdaten der Quidelortho Corporation-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quidelortho Corporation-Aktie (QDEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Busky Joseph M. | Chief Financial Officer |
Feb 13 '26 |
Buy |
23.66 |
3,370 |
79,742 |
10,290 |
| Blaser Brian J. | President and CEO |
Feb 13 '26 |
Buy |
23.59 |
10,540 |
248,661 |
40,073 |
| RHOADS ANN D | Director |
Dec 10 '25 |
Buy |
28.27 |
750 |
21,206 |
15,021 |
| Wilkins Joseph D Jr. | Director |
Nov 26 '25 |
Buy |
27.95 |
370 |
10,343 |
11,876 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Option Exercise |
15.74 |
7,021 |
110,511 |
41,087 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Sale |
27.81 |
4,026 |
111,965 |
37,061 |
1.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):